If insulin-induced decreased sensitivity to antitumor drugs can be ascribed to P-glycoprotein, the reversal of P-glycoprotein-mediated resistance is likely to work in the treatment of those obese patients who are not sensitive to conventional anti-cancer regimens. This evidence concerns the gene ABCB1 and cancer.